4103 Results

People

  1. Hudis
    Hudis
  2. Robson
    Robson
  3. Norton
    Norton
  4. Rosen
    Rosen
  5. Seidman
    Seidman
  6. Offit
    Offit
  7. Chandarlapaty
    Chandarlapaty
  8. Dang
    Dang
  9. Modi
    Modi
  10. Solit
    Solit

Groups

  1. Breast Medicine Service (4103)
  2. Department of Medicine (4103)
  3. Solid Tumor Oncology Division (4103)
  4. Survivorship Research (2337)
  5. GSK Faculty (1492)
  6. Population Sciences Research Program (1339)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1128)
  8. Epidemiology and Biostatistics (863)
  9. Human Oncology and Pathogenesis Program (702)
  10. Department of Pathology and Laboratory Medicine (678)
  1. "Breast Medicine Service"
Formats
  1. Journal Article (2170)
  2. Meeting Abstract (1650)
  3. Review (78)
  4. Book Section (67)
  5. Editorial (42)
  6. Conference Paper (28)
  7. Guidelines (26)
  8. Correspondence (16)
  9. Miscellaneous (11)
  10. Research Letter (10)
  11. Book Whole (5)
Groups
  1. Breast Medicine Service (4103)
  2. Department of Medicine (4103)
  3. Solid Tumor Oncology Division (4103)
  4. Survivorship Research (2337)
  5. GSK Faculty (1492)
  6. Population Sciences Research Program (1339)

More Groups

People
  1. Clifford Hudis (905)
  2. Larry Norton (758)
  3. Mark Robson (676)
  4. Neal Rosen (425)
  5. Andrew Seidman (318)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (57)
  2. 2024 (192)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (802)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (169)
  4. Annals of Oncology (158)
  5. Clinical Cancer Research (128)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (853)
  2. American Association for Cancer Research (749)
  3. Springer (329)
  4. Elsevier Inc. (322)
  5. Oxford University Press (278)
  6. Nature Publishing Group (273)

More Publishers

Results (4103)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Antagonists for constitutively active mutant estrogen receptors: Insights into the roles of antiestrogen-core and side-chain
    Journal Article

    Sharma, A.; Toy, W.; Guillen, V. S.; Sharma, N.; Min, J.; Carlson, K. E.; Mayne, C. G.; Lin, S.; Sabio, M.; Greene, G.; more...
    ACS Chemical Biology (2018)

    Fulltext@MSK | Save
  • In reply
    Journal Article

    Dang, C. T.; Singh, J. C.; Steingart, R. M.; Yu, A. F.
    The Oncologist (2018)

    Fulltext@MSK | Save
  • BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
    Journal Article

    Cline, M. S.; Liao, R. G.; Parsons, M. T.; Paten, B.; Alquaddoomi, F.; Antoniou, A.; Baxter, S.; Brody, L.; Cook-Deegan, R.; Coffin, A.; more...
    PLoS Genetics (2018)

    Fulltext@MSK | Save
  • The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
    Journal Article

    Fanning, S. W.; Jeselsohn, R.; Dharmarajan, V.; Mayne, C. G.; Karimi, M.; Buchwalter, G.; Houtman, R.; Toy, W.; Fowler, C. E.; Han, R.; more...
    eLife (2018)

    Fulltext@MSK | Save
  • Detecting HER2 alterations by next generation sequencing (NGS) in patients with advanced NSCLC from the United States and China
    Meeting Abstract

    Xu, C.; Zhang, Y.; Liu, D.; Shen, R.; Razavi, P.; Liu, S.; Sun, H.; Offin, M.; Drilon, A.; Rudin, C.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase 1 study of DS-8201a in HER2-expressing or -mutated advanced non-small-cell lung cancer
    Meeting Abstract

    Tsurutani, J.; Park, H.; Doi, T.; Modi, S.; Takahashi, S.; Nakagawa, K.; Krop, I.; Waqar, S.; Yoh, K.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
    Meeting Abstract

    Baselga, J.; Dent, S. F.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Verma, S.; Wilson, T. R.; Jin, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pan-cancer microsatellite instability to predict for presence of Lynch syndrome
    Meeting Abstract

    Latham Schwark, A.; Srinivasan, P.; Kemel, Y.; Shia, J.; Bandlamudi, C.; Mandelker, D.; Dubard-Gault, M.; Tran, C.; Middha, S.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer
    Meeting Abstract

    Soliman, H. H.; Robson, M. E.; Wagner, S.; Flake, D. D.; Schwartzberg, L. S.; Sharma, P.; Magliocco, A. M.; Kronenwett, R.; Lancaster, J. M.; Lanchbury, J. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial
    Meeting Abstract

    Jhaveri, K. L.; Makker, V.; Wang, X. V.; Chen, A. P.; Flaherty, K.; Conley, B. A.; O'Dwyer, P. J.; Williams, P. M.; Hamilton, S. R.; Harris, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save